The Medipattern Corporation

The Medipattern Corporation

December 17, 2007 06:30 ET

Medipattern Installs B-CAD™ in Italy

B-CAD standardizes reporting in concert with GE LOGIQworks System

TORONTO, ONTARIO--(Marketwire - Dec. 17, 2007) - The Medipattern Corporation (TSX VENTURE:MKI), an award-winning developer of computer-aided detection (CAD) medical imaging software designed to aid physicians in making better informed biopsy decisions and to permit a higher standard of care for the millions of patients at risk of cancer, is pleased to announce the installation of B-CAD 2.0 at General Hospital in Gorizia, Italy. B-CAD is analyzing images created on the GE Healthcare LOGIQ® 9 Ultrasound System and sent to the GE Healthcare LOGIQworks radiologist review station. B-CAD analyzes the specified regions of interest, finding the edge of the lesion and identifying characteristics which indicate that the lesion is probably benign or probably malignant. B-CAD then collects the information into a natural language report, which is communicated to LOGIQworks for inclusion with the images in the patient record. The system provides a single station for reading, using CAD, reporting, and finalizing the report - a breakthrough in streamlining workflow for the entire process from image capture to reporting.

"B-CAD brings standardization to diagnostic breast ultrasound. Using B-CAD and LOGIQworks shows superior image quality in a format that is easily read. B-CAD ensures that every radiologist in the practice goes through the features checklist quickly," said Dr. Giorgio Rizzatto, Director of Diagnostic Imaging in Gorizia. "B-CAD automatically detects and identifies all of the characteristics of the lesion. The radiologists check the findings and can add to or modify the findings as needed. Using CAD to complete the reporting package saves time and is a constant reminder to check every feature to ensure gathering all of the evidence needed to make a diagnostic decision. The combination of B-CAD with LOGIQworks puts reading and reporting into one totally fluid environment. Prior to this implementation, reporting was always on one system and reading was on another, which forced the radiologist to move between computers several times to completely read and document each case."

"Dr. Rizzatto is a globally recognized thought leader in breast ultrasound," said Jeff Collins, CEO and co-founder of Medipattern. "Dr. Rizzatto has long seen and advocated for the need to have an international standard to define and characterize breast lesions - a need which B-CAD supports. His active work in several organizations is bringing breast imaging to a greater level of understanding. We are honored to have all of the physicians at General Hospital and most especially Dr. Rizzatto as clients."

Upcoming Events:

Medipattern will participate in the following events:

- European Congress of Radiology (ECR), March 7 to 11, Vienna, Austria.

- American Institute of Ultrasound in Medicine (AIUM), March 12 to 15, San Diego, CA.

The Medipattern Corporation

Medipattern develops computer-aided detection (CAD) solutions for medical imaging. These products enhance workflow while improving interpretive and diagnostic confidence. The Company's initial clinical applications are B-CAD™ for breast ultrasound and B-CADMRI™. Both have received awards for innovation in the industry. The B-CAD products, part of the Company's CADENZA™ platform, use pattern recognition technology to assist radiologists in their efforts to classify and characterize lesions in medical images. Please visit the company's website at:

B-CAD™ and B-CADMRI™ are trademarks of The Medipattern Corporation.

Medipattern® is a registered mark of The Medipattern Corporation.

Forward-looking statements

This document contains forward-looking statements relating to Medipattern's performance, operations, or business environment. These statements are based on what we believe are reasonable assumptions given currently available information and our understanding of Medipattern's current activities. We have tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential", and similar expressions. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict or control. A number of factors could cause actual outcomes and results to differ materially from those expressed in forward-looking statements. These factors include but are not limited to those set forth in the Company's corporate filings, (posted at In addition, these forward-looking statements relate to the date on which they are made. The Company disclaims any intention or obligation to update or revise any forward-looking statements for any reason. Readers should not rely on forward-looking statements.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release and has neither approved nor disapproved of the contents of this release.

Contact Information